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Abstract 
Oncolytic viruses induce local tumor destruction and inflammation. Whether virotherapy can also 
overcome immunosuppression in non-infected tumor areas is under debate. To address this question, we 
have explored immunologic effects of oncolytic herpes simplex viruses (oHSV) in a genetically 
engineered mouse model of IDH wildtype glioblastoma, the most common and most malignant primary 
brain tumor in adults. Our model recapitulates the genomics, the diffuse infiltrative growth pattern, and 
the extensive macrophage-dominant immunosuppression of human glioblastoma. Infection with an 
oHSV that was armed with a ULBP3 expression cassette inhibited distant tumor growth in the absence of 
viral spreading (abscopal effect) and yielded accumulation of activated macrophages and T-cells. There 
was also abscopal synergism of oHSVULBP3 with anti-Pd1 against distant, uninfected tumor areas, albeit 
consistent with clinical trials in glioblastoma patients, monotherapy with anti-Pd1 was ineffective in our 
model. Arming oHSV with ULBP3 led to up-regulation of antigen processing and presentation genesets 
in myeloid cells. The cognate ULBP3 receptor NKG2D is however not present on myeloid cells, 
suggesting a non-canonical mechanism of action of ULBP3. Overall, the myeloid-dominant, anti-Pd1-
sensitive abscopal effect of oHSVULBP3 warrants further investigation in patients with IDH wildtype 
glioblastoma. 
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Introduction 
Glioblastoma, the most common primary malignant brain cancer in adults, is an invariably 
deadly disease with median overall survival in the range of 12 months (1). The advent of 
immunotherapy prompted a plethora of clinical trials seeking to overcome the distinctive 
immunosuppression of these tumors, but phase III immunotherapy clinical trials of various 
strategies in glioblastoma patients have failed to prolong survival (2). The tumor 
microenvironment of glioblastoma is dominated by immunosuppressive tumor-associated 
microglia and macrophages (TAM) that limit immune surveillance by lymphocytes (3).  
 
Preclinical exploration of microenvironment modulating therapies requires bona fide cancer 
models with histologic and immunologic features that resemble their human counterparts as 
closely as possible. Applying a sequential bioinformatics and genetic engineering approach to 
identify and subsequently model relevant oncogenic events, we have previously generated mouse 
glioblastoma models that develop in situ from the mice’s own cells and that are histologically 
and molecularly highly similar to human glioblastoma (4).  
 
Promising response rates and translational data from early phase biological endpoint trials 
support the rationale and feasibility of virotherapy approaches to revert immunosuppression in 
glioblastoma (5-7). Oncolytic viruses are usually administered locally, either directly into the 
tumor, or into the resection cavity during surgery. In order to be efficacious in patients with 
disseminated tumors or multifocal cancer, virotherapy will however need to induce distant anti-
cancer immune responses beyond local tumor cell lysis.  
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Here, we explored localized and distant (abscopal) immunologic effects of oncolytic virotherapy 
in a genetically engineered, immunologically inert model of diffusely infiltrating glioblastoma. 
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Results 
 
Immunologic properties of genetically engineered IDH wildtype glioblastoma  
 
The vast majority of glioblastomas are classified by the lack of IDH mutations and harbor gain of 
chromosome 7, loss of heterozygosity of chromosome 10 and homozygous deletion of CDKN2A 
(4, 8)(Figure S1A). We have utilized the RCAS/tv-a gene transfer system in N/tv-a;Cdkn2a-/-
;Ptenfl/fl;LucLSL/LSL (XFM-Luc) mice to generate IDH wildtype glioblastomas in situ from the 
mice’s own cells. Nestin-positive neural stem- and progenitor cells in XFM-Luc mice were 
infected with RCAS-PDGF to model chromosome 7 gain, and with RCAS-Cre to model loss of 
chromosome 10 (XFM-Luc:PDGF,Cre) (4)(Figure S1B).  
 
Immunohistochemistry of mouse and human IDH wildtype glioblastomas suggested that key 
components of the immune cell compartment are similar between our genetically engineered 
mouse glioblastomas and their human counterparts. There was a vast abundance of Iba1+ TAMs, 
which accumulated in zones of pseudopalisading necrosis, whereas Cd3+ tumor-infiltrating 
lymphocytes were hardly detected (Figure 1A). Flow cytometry confirmed that XFM-
Luc:PDGF,Cre glioblastomas have few if any lymphocytes and that the majority of Cd45+ cells 
were of myeloid origin, predominantly comprising bone-marrow derived macrophages 
(Cd45high;Cd11b+;Ly6clow;Ly6g-, mean 53%, Figure 1B). Consistent with the only completed 
phase III clinical trial of immune checkpoint inhibition in patients with glioblastoma (9), various 
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immune checkpoint inhibitors had no effect on the survival of XFM-Luc glioblastoma-bearing 
mice (Figure 1C). 
 
Our model reflects the immune phenotype of its human counterpart (3) and circumvents major 
limitations of commonly utilized syngeneic cancer models, including hypermutation, lymphocyte 
accumulation and an inherent response to immune checkpoint inhibition (10, 11).  
 
 
oHSVULBP3 leverages accumulation of activated TAMs 
 
We have utilized this IDH wildtype glioblastoma model as a paradigm to develop an oHSV, 
which we optimized for the treatment of glioblastoma utilizing a miR-124-based attenuation 
strategy (12) (Figure S2A-E, Note S1). Moreover, as a means to augment an expected 
virotherapy-induced immune response, we generated an oHSV, which included a payload 
cassette to drive the expression of human UL16-binding protein 3 (ULBP3), a class 1 major 
histocompatibility complex (MHC)-like molecule and member of the family of ligands of the 
killer cell lectin-like receptor subfamily K member 1 (NKG2D). NKG2D-independent pro-
inflammatory effects on myeloid cells have been reported for ULBP3, but not for ULBP1 or 
ULBP2 (13), rendering ULBP3 our prime candidate payload to revert the macrophage-dominant 
immunosuppression of glioblastoma. 
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Mice bearing XFM-Luc:PDGF,Cre glioblastomas were randomized to undergo intratumoral 
injection of PBS, oHSV or oHSVULBP3 (Figure 2A). oHSVULBP3 prolonged median survival after 
treatment from 8 to 18 days (hazard ratio [HR] 0.28, p<0.001) and inhibited tumor growth as 
assessed by luminescence imaging (p=0.013), whereas oHSV lacking the ULBP3 payload 
cassette did not (HR 1.02, p=0.94, Figure 2B, Figure S2F). Therefore, we focused our further 
efforts on oHSVULBP3 to determine its utility as an investigational new drug.  
 
Histopathological analysis of glioblastoma-bearing mice sacrificed on day 7 after intratumoral 
injection of oHSVULBP3 revealed necrotic areas in zones of viral replication in 4 of 4 analyzed 
mice indicating oncolysis (Figure 2C). Viral replication and oncolysis were generally restricted 
to small foci surrounding the injection site. Immunohistochemistry staining identified 
accumulation of Iba1+ myeloid cells in eGFP+ zones of oHSVULBP3 replication (Figure 2D). 
Computed imaging analyses of Iba1-stained tumor sections (N=4 per group, day 7 after viral 
infection) revealed that upon treatment with oHSVULBP3 the overall tumor area covered with 
Iba1+ cells increased by >2-fold compared to PBS-injected tumors (p=0.016), but oHSV lacking 
the ULBP3 expression cassette did not have that effect (p=0.66, Figure 2E).  
 
 
oHSVULBP3 leverages accumulation of activated T cells 
 
We have considered adding ULBP3 primarily to strengthen oHSV-induced anti-viral T-cell 
responses, because its cognate human receptor NKG2D amplifies the cytotoxicity of activated T-
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cells in addition to activating NK-cells (14). There was indeed an increase in Cd8+ T-cells in 
oHSVULBP3-treated tumors (mean Cd8+ cells per HPF in PBS vs oHSVULBP3 = 2 vs 19, N=4 per 
group, p=0.015), but not in tumors treated with an oHSV that was lacking ULBP3 (p=0.14, 
Figure 2F). The number of tumor-infiltrating FoxP3+ regulatory T-cells increased from 1 to 7 
per HPF upon treatment with oHSVULBP3 (p=0.018), but the ratio of Cd8+/FoxP3+ increased 
from 2 to 3 (p=0.020, Figure S2G). oHSVULBP3-driven Cd8+ T-cell influx was further enhanced 
by co-treatment with anti-Pd1 (p=0.003), but anti-Pd1 had no effect on Cd8+-influx in the 
absence of virotherapy (p=0.55, Figure S2H). There was also synergism of oHSVULBP3 and anti-
Pd1 in promoting the Cd8+;Cd44-;Cd62L- effector T-cell phenotype from 1% in PBS-treated 
tumors to 15% of Cd8+ cells in oHSVULBP3 plus anti-Pd1 co-treated tumors (p=0.002). 
Interestingly, both treatments given as mono-therapy had only minor effects on the effector T-
cell fraction (Figure S2I). By contrast, flow cytometry determined only a minor increase in NK-
cells on day 7 after treatment with oHSVULBP3 (p=0.026, Figure S2J). This increase was 
accompanied by a decrease in Cd69+ activated NK-cells (p=0.036, Figure S2K) and loss of 
Nkg2d (% Nkg2d+ of  NK-cells upon treatment with PBS vs oHSVULBP3 = 21 vs 3, p<0.001, 
Figure S2L), indicating that NK-cells were likely not the driving force of the observed survival 
benefit. 
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oHSVULBP3 promotes antigen presentation and toll-like receptor signaling 
 
In order to characterize the effects of oHSVULBP3 on the tumor microenvironment in more detail, 
we performed nCounter gene expression analyses utilizing two gene panels, myeloid innate 
immunity and immunology (N=5 tumors per group and panel).  Within the myeloid innate 
immunity gene panel (N=732 genes), there were N=461 genes that were >2-fold upregulated and 
N=10 genes that were >2-fold downregulated in tumors injected with oHSVULBP3 versus PBS 
(Figure 2G). Geneset enrichment analysis of genes up-regulated upon oHSVULBP3 treatment 
versus PBS identified the gene ontology (GO) terms antigen presentation (p=0.002) and toll-like 
receptor (TLR) signaling (p=0.002, Figure 2H). Both genesets were also upregulated in tumors 
treated with oHSVULBP3 versus oHSV (antigen presentation, p=0.043; TLR signaling, p=0.043), 
suggesting a ULBP3-mediated effect. Similar analyses of the immunology gene panel (N=545 
genes) in tumor-bearing mice treated with oHSVULBP3 versus PBS identified enrichment of the 
Kyoto encyclopedia of genes and genomes (Kegg) genesets phagosome (p=0.023) and confirmed 
enrichment of antigen processing and presentation (p=0.004) as well as a trend for increased 
TLR signaling (p=0.065) upon oHSVULBP3 treatment (Figure S2M).  
 
The dominance of a myeloid immune response was surprising in the light of putative NKG2D-
mediated effects of ULBP3. Since the cognate ULBP3 receptor Nkg2d is not present on myeloid 
cells, we assume a non-canonical mechanism of action of ULBP3. A previous study utilizing the 
EL4 and RMA mouse tumor models demonstrated that ectopic expression of human ULBP3 in 
murine tumor cells results in tumor rejection, but failed to demonstrate binding of ULBP3 to 
murine Nkg2d (13). Structure interaction modeling utilizing the protein modeling portal (15) 
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predicted a weak, if any, physical interaction of human ULBP3 with human NKG2D, and 
suggested that human ULBP3 did not bind to the mouse orthologue of NKG2D (Figure S2N). 
Flow cytometry of human peripheral blood mononuclear cells and murine splenocytes utilizing 
Fc-tagged recombinant ULBP3 confirmed binding of ULBP3 to NKG2D-negative myeloid cells; 
pretreatment with NKG2D blocking antibodies did not abrogate ULBP3 binding to myeloid cells 
(Figure S2O). Collectively, these data suggest a non-canonical mechanism of action of ULBP3 
that drives antigen processing and presentation through interaction with an unknown receptor on 
myeloid cells. This notion is supported by publically available data from mass spectrometry 
based affinity capture experiments in human cell lines, which identified 19 ULBP3 binding 
partners (16) which are also enriched for the GO term antigen processing and presentation 
(Figure S2P). In humans, ULBP3 is in addition a cognate ligand of NKG2D, suggesting that in 
patients, oHSVULBP3 may exert additional favorable immune modulating effects through 
activation of NK and T cells via NKG2D. 
 
 However, while our study supports a model of pleiotropic effects of ULBP3, anti-tumor activity 
could also result from the generation of opsonizing antibodies directed against soluble Nkg2d 
ligands (17). More in-depth research will be required to determine the precise mechanism by 
which ULBP3 activates macrophages. 
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Abscopal accumulation of activated T-cells upon localized oHSVULBP3 infection  
 
We reasoned that virotherapy could only be effective against metastasizing or diffusely 
infiltrating cancers such as glioblastoma if an anti-cancer immune response was elicited not only 
locally, but also distant from the site of tumor infection, i.e. by exerting an abscopal effect. In 
order to model oHSV-infected and uninfected tumor portions, we generated to spatially 
segregated tumors in both hemispheres of XFM-Luc mice. In this modified bilateral 
glioblastoma model, luciferase was activated only in the untreated tumor portion (Figure S3A), 
allowing to monitor abscopal growth independent of local effects of virotherapy.  
 
We then utilized this model to explore abscopal effects of localized oHSVULBP3 therapy (Figure 
3A). Unilateral treatment with oHSVULBP3 inhibited contralateral tumor growth (Figure 3B) and 
prolonged survival (HR 0.49, p=0.003, Figure 3C). Of note, contralateral, Luc+ tumor lesions 
were survival-limiting (Figure S3B)(4), indicating that the survival benefit from unilateral 
treatment was due to abscopal inhibition of tumor growth. The lack of any survival effect of 
oHSV without the ULBP3 expression cassette (Figure 2) and the lack of viral replication in 
normal brain cells (Note S1) suggested that infection and replication of oHSVULBP3 in the tumor 
was a prerequisite for inducing an abscopal effect. There was also abscopal sensitization to 
immune checkpoint inhibition with anti-Pd1, which translated into prolonged survival among 
those mice that survived for at least 7 days (HR 0.31, p=0.014, N=5-6 mice per treatment arm, 
Figures 3C and S3C).  
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Flow cytometry of paired oHSVULBP3-treated and contralateral untreated tumor areas (XFM-
Luc:PDGF,Cre) determined a bilateral >2-fold increase of the Cd45+ bone marrow-derived 
immune cell fraction 7 days after virotherapy (Figure 3D). Utilizing a customized nCounter high-
sensitivity gene expression array, the detection of viral RNA was locally restricted to treated 
tumors (Figure S3D), thus precluding that viral spread caused the abscopal accumulation of 
Cd45+ cells. 
 
There was abscopal T-cell memory formation, activation and exhaustion. By day 3 after 
unilateral oHSVULBP3 treatment, there was a bilateral induction of Cd44+;Cd62L+ central 
memory T-cells in both the Cd4+ and Cd8+ tumor-infiltrating lymphocyte fractions (Figure 
S3E), suggesting that the abscopal effect involves T-cell memory. The fraction of Cd8+ tumor-
infiltrating lymphocytes positive for the activation markers Cd69 or Nkg2d increased 
simultaneously in virus-treated tumors and abscopally in 5 of 5 mice (Figure S3F). By contrast, 
the Cd8+;Cd44-;Cd62L+ naïve lymphocyte fraction was almost completely suppressed 
bilaterally (Figure S3G). The rationale for combining oHSVULBP3 with anti-Pd1 was further 
supported by a 3-fold increase in the fraction of Pd1+;Tim3+ exhausted Cd8+ T-cells in 
oHSVULBP3 treated tumors (8 of 8 analyzed tumors, p<0.001), and a >1.5-fold abscopal increase 
(6 of 8, p=0.022, Figure S3H). 
 
Immunohistochemistry of untreated contralateral tumors also revealed an abscopal increase in 
total infiltrating Cd8+ T-cells upon ipsilateral oHSVULBP3 treatment in 2 of 4 analyzed tumors 
(p=0.13), and this trend was further augmented to a mean 12-fold increase in abscopal Cd8+ 
tumor infiltration upon co-treatment with anti-Pd1 (p=0.003, Figure 3E). In line with flow 
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cytometry findings, the morphological notion of an enlarged cytoplasm and vesicles 
accumulating at the cellular membrane were suggestive of an activated state of these Cd8+ cells 
(Figure 3F). In summary, these data indicate that oHSVULBP3 initiates an abscopal T-cell 
response that can be augmented utilizing immune checkpoint inhibition with anti-Pd1. 
 
 
Abscopal TAM accumulation and activation upon localized oHSVULBP3 infection 
 
Since the model used here does not contain known non-synonymous mutations, it remains 
elusive which (neo-)antigens could have triggered bilateral accumulation and activation of T-
cells upon unilateral oHSVULBP3 treatment. Human glioblastoma likewise carries only few non-
synonymous mutations (18), but naturally occurring T-cell responses directed against tumor-
associated antigens of development-associated genes have been reported (19). Whether similar 
antigens elicit T-cell responses in mouse glioblastomas is not known. In fact, the observed 
bilateral influx of activated T-cells could have been an epiphenomenon of a unilateral T-cell 
response against HSV antigens or against ULBP3, which is a foreign antigen in the mouse too, 
followed by surveillance of the entire brain. This possibility indicates that direct killing of tumor 
cells by macrophages could account for the majority of the observed anti-tumor effect of 
oHSVULBP3, at least in untreated tumor lesions where viral replication did not occur and where 
therefore foreign antigens were not present. 
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To explore this possibility, we sought to characterize the oHSVULBP3-driven myeloid immune 
cell infiltrate in more detail. We did time course analyses of tumor-infiltrating Cd45+ cells by 
flow cytometry of oHSVULBP3-treated tumors and contralateral untreated tumors in the bilateral 
XFM-Luc:PDGF,Cre glioblastoma model. There was an early bilateral influx of monocytes 
(Cd45+;Cd11b+;Ly6c+) in 8 of 8 mice peaking at day 3 after virotherapy in both, ipsilateral, 
treated tumors (>5-fold, p<0.001), and abscopally (>4-fold, p<0.001, Figure 4A). 
Immunohistochemistry for Iba1 confirmed an abscopal increase of TAM (1.5-fold, p=0.014) in 4 
of 4 analyzed tumors upon unilateral oHSVULBP3 treatment, and anti-Pd1 treatment further 
augmented that abscopal effect in 2 of 4 untreated tumors (p=0.040), although we noted no effect 
of anti-Pd1 monotherapy on TAM accumulation (p=0.90, Figure S4A). Interestingly, 
immunohistochemistry also revealed that ipsilateral treatment with oHSVULBP3 yielded abscopal 
relative exclusion of Iba1+ TAMs from pseudopalisades and transformation towards a phenotype 
suggestive of phagocytosis and potentially pro-inflammatory activation (Figure 4B). In line with 
the notion of bilateral macrophage activation upon unilateral treatment with oHSVULBP3, flow 
cytometry determined a bilateral >3-fold bilateral increase in cells expressing the macrophage 
activity marker Cd44, which persisted by day 14 after unilateral oHSVULBP3 infection (Figure 
S4B). There was also upregulation of MHC-II molecules on the cell surface of Cd11c+;MHC-II+ 
cells upon oHSVUBLP3 treatment both, ipsilaterally (p=0.007) in 7 of 7, and in 6 of 7 contralateral 
untreated tumors (p=0.011, Figure S4C). Gene expression analyses of tumors contralateral to 
oHSVULBP3-treatment were also suggestive of pro-inflammatory TAM repolarization, including a 
>4-fold increase of the Cd68/Cd163 ratio (p=0.005, Figure S4D), and up-regulation of MAPK 
signaling (p=0.003) and NFκB signaling (p=0.003, Figure S4E).  
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TAM activation yields up-regulation of the immune checkpoint receptor Pd1, and activation of 
Pd1 by its main ligand Pdl1 drives immunosuppressive repolarization of TAM (20).  Flow 
cytometry of bilateral XFM-Luc:PDGF,Cre glioblastomas determined Pd1 on more than 70% of 
TAM in both, oHSVULBP3 treated tumors and abscopally, compared to approximately 20% Pd1+ 
TAM in PBS-treated tumors (Figure 4C). As an add-on to virotherapy, anti-Pd1 treatment was 
also associated with enrichment of the antigen presentation geneset in both oHSVULBP3 treated 
tumor lesions (p=0.037) and abscopally in untreated tumor areas (p=0.017, Figure 4D,E).  
Upon treatment with anti-Pd1 alone (10 mg/kg i.v. every other day), nCounter gene expression 
analysis (5 mice/group) of a myeloid innate immunity panel determined enrichment GO terms 
associated with pro-inflammatory processes, including antigen presentation (p<0.001), interferon 
signaling (p<0.001) and TLR signaling (p=0.012, Figure S4F). Similar enrichment patterns could 
be determined by Kegg geneset enrichment analysis (Figure S4G). 
Similar analyses applying the nCounter immunology gene panel identified abscopal enrichment 
of the KEGG genesets phagosome (p=0.008) and TLR signaling (p=0.032) when anti-Pd1 was 
added to oHSVULBP3. These data indicate that combination with anti-Pd1 augments TAM-driven 
local and abscopal effects of oHSVULBP3.  
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Discussion 
 
Oncolytic virotherapy has emerged as a viable approach to revert immunosuppression in 
immunologically “cold” cancers, including glioblastoma (2, 5-7, 21-29). Here, we have 
employed a miR-124-based oHSV attenuation system that circumvents interferon sensitivity 
conveyed by the commonly utilized ICP-34.5 loss of function attenuation strategy (12). Arming 
our miR-124-attenuated oHSV with ULBP3 promoted a localized and abscopal anti-cancer 
immune response and sensitized to anti-Pd1 in a clinically relevant genetic glioblastoma model 
(4). 
 
The notion of direct tumor cell killing by activated macrophages is consistent with pre-clinical 
reports in other entities, e.g. non-hypermutated colon cancer (30). Moreover, the pro-
inflammatory effect of anti-Pd1 on myeloid cells in virus-injected and distant, untreated tumor 
areas underscores the role of Pd1-signaling as an inhibitory pathway in tumor-macrophages (20) 
and supports combination treatments of oHSV with anti-Pd1 irrespective of tumor T-cell 
infiltration.  
 
Extensive TAM infiltration and activation followed by an adaptive immune response following 
virotherapy has been reported previously, including in syngeneic glioblastoma models (27, 31). 
Beyond the necessity of macrophage repolarization for establishing an adaptive immune 
response, our data also support previous reports on the role of TAM for the clearance of oHSV-
infected cells (32, 33). Similar effects of NK-cells have also been reported to limit the efficacy of 
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oHSV treatment (34), albeit in our model down-regulation of activation markers and the low 
abundance of NK-cells suggest that mainly TAM have limited viral spreading.  
 
A previous report on the combination treatment of an oHSV with immune checkpoint inhibition 
in a therapeutically challenging immune-suppressed glioblastoma model demonstrated that 
TAMs and T-cells are both required to exert efficacious anti-tumor effects (27). The observed 
dominance of a myeloid immune response in our model may have several reasons: (i) gene 
expression changes in the lymphocytic compartment were likely covered by myeloid- and tumor-
associated gene expression patterns due to the relatively lower abundance of lymphocytes. (ii) 
Our genetic in situ modeling approach does not convey potentially immunogenic neo-antigens, 
thus likely limiting the efficacy of T-cell infiltration. (iii) The short survival time of our model 
may not suffice to fully establish an anti-cancer T-cell response, i.e. the observed infiltration of 
activated T-cells may be no more than the onset of such a response. Therefore, depleting 
macrophages (e.g. utilizing clodronate liposomes) will likely have a more prominent effect than 
depleting Cd8 T-cells in our model, but the translational relevance of such findings will be 
limited by the above-mentioned characteristics of our model. 
 
Yet, our model also conveys major advantages over commonly utilized syngeneic glioblastoma 
models, including (i) the omission of cell culture artifacts by inducing tumors in situ from the 
mice’s own cells, (ii) the presence of oncogenic driver events that are indeed present in human 
glioblastoma (versus random oncogenic transformation by chemical induction or ex vivo 
overexpression of oncogenes that are rare in glioblastoma, e.g. mutated RAS), and (iii) a 
distinctive lymphocyte depletion in untreated tumors.  
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In summary, the herein presented data support further development of virotherapy as a means to 
sensitize cancers to immune checkpoint inhibition, including in diffusely infiltrating brain 
cancers where only a subset of cells can be infected. 
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Methods 
 
Genetically engineered mouse glioblastoma model 
 
All animal experiments were done in accordance with guidelines from the Institutional Animal 
Care and Use Committees of Fred Hutchinson Cancer Research Center. The RCAS/Tva model 
system was used to generated mouse glioblastomas (35). N/tva; Cdkn2a/b-/-; Ptenflox/flox; LSL 
Luciferase mice were used as genetic backgrounds for RCAS mediated glioblastoma formation. 
For a bilateral tumor model, following introduction of RCAS-PDGFB with RCAS-Cre into one 
hemisphere and RCAS-PDGFB with RCAS-shPten into the contralateral hemisphere for 
bioluminescence, two genetically similar tumors are present where one tumor lacks luciferase 
expression (PDGFB/shPten; treated glioblastoma) and another tumor with luciferase expression 
(PDGFB/Pten-/- Luciferase; distant glioblastoma for assessment of abscopal response). Tumors 
were generated in 4-6-week-old male and female adult mice injected with 2x105 DF1 cells 
delivered with a 30-gauge needle attached to a Hamilton syringe and stereotactic fixation device 
(Stoelting, Wood Dale, IL). Cells were injected into the frontal cortex of each hemisphere: 
Coordinates were lateral to bregma 3mm at a depth of 1mm. Treatment began 14 days after 
tumor formation.  
The RCAS vectors used were generated as previously described (4). Briefly, DF1 cells were 
purchased from ATCC and grown at 39ºC. Transfections with RCAS vectors were performed 
using the Fugene 6 transfection kit (Roche E2691). Nestin-specific, Cre-recombinase responsive 
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PDGF-luciferase expressing mouse models were monitored until they developed signs of tumor 
burden including lethargy, poor grooming, weight loss, macrocephaly, seizure and paralysis.  
 
 
Virotherapy and drug treatments in vivo 
 
Adult mice were sedated with isoflurane. The same coordinates as for tumor initiation were 
utilized for oncolytic virus treatment. Injection of 106 PFU of indicated oHSV strains in 1 µl 
PBS, or 1 µl PBS alone, were injected over 2 minutes utilizing a 30 gauge needle attached to a 
Hamilton syringe and stereotactic fixation device. In the double-tumor model, only one tumor 
was injected. The same stereotactic coordinates as for tumor formation were utilized.  
Endotoxin low (≤0.001 EU/µg; ≤ 1 EU/mg) anti-Ctla4, anti-Pdl1, anti-Pd1, or indicated isotype 
controls (10µg/g mouse body weight, see Table S1) were administered starting on the day of 
virotherapy and then every other day until endpoint. Bioluminescence signals were obtained for 
each treatment group every 2-3 days following treatment. The last bioluminescence signal 
represents the last time point measured prior to reaching end-point (See Kaplan-Meier curve for 
end-points). Animals were sacrificed upon development of neurological symptoms as defined by 
the Institutional Animal Care and Use Committee.  
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Bioluminescence  
 
Bioluminescence imaging was obtained on the Xenogen IVIS 100 system. Mice with tumors 
expressing luciferase were anesthetized with isofluorane before retroorbital injection with 
75mg/kg body weight D-luciferin (Caliper Life Sciences Part Number #119222). Promptly after 
injection, repeat images were acquired for 3-5 minutes to ensure that the plateau phase of photon 
emission was reached. Total flux (photons seconds-1) was obtained from each mouse.  
 
 
Immunohistochemistry and immunofluorescence 
 
Mouse brains were fixed in formalin and embedded in paraffin, then sectioned at 5m and 
stained by routine hematoxylin and eosin (H&E), as well as immunohistochemistry (IHC) or 
immunofluorescence (IF). Automated IHC and antigen retrieval for IF was performed on the 
Discovery XT (Ventana Medical Systems Inc.) according the manufacturers standard protocol. 
For IF, after washing with TBS, a blocking step with TBS containing 10% donkey serum of 1 
hour, sections were rinsed with TBS and incubated in a mixture of indicated antibodies of each 
series in TBS containing 2% bovine serum albumine overnight at 4°C. After washing in TBS, a 
cocktail of indicated secondary antibodies was applied for 4 hours at room temperature. Sections 
were washed again, mounted and coverslipped in polyvinyl alcohol with diazabicyclo-octane 
(DABCO) as an anti-fading agent. Images were acquired using a Zeiss LSM 780 NLO confocal 
microscope.  
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Gene expression analysis 
 
Paraffin embedded tissue sections were macro dissected and RNA extracted utilizing the RNeasy  
FFPE kit (Qiagen; 73504). Contaminating DNA was removed with DNase (Thermo Fisher; 
EN0525). 50ng of total RNA was hybridized at 96°C overnight with the nCounter mouse 
immunology and myeloid innate immunity panels (NanoString; XT-CSO-MIM1-12, XT-CSO-
MMII2-12). Hybridized samples were analyzed for frequency of each RNA species using the 
nCounter SPRINT™ profiler (NanoString). Raw mRNA abundance frequencies were analyzed 
using the nSolver™ analysis software 2.5 pack. Normalization factors were derived from the 
geometric mean of housekeeping genes, after QC with built in negative and positive controls.  
 
 
Flow cytometry 
 
Animals were sacrificed, and their brains were removed from the skull immediately after cardiac 
perfusion with 10 mL of ice cold PBS. Mouse brains were mechanically dissociated and gently 
forced through a 70-µm strainer followed by rinsing with 50 mL of Hank's balanced salt solution 
(HBSS) + 10% fetal bovine serum (FBS). Cells were pelleted by centrifugation (500g for 10 min 
at 4°C) and suspended in red blood cell (RBC) lysis buffer (5 mL per brain, 1 min on ice). RBC 
lysis was quenched by adding 3 volumes of HBSS + 10% FBS, and cells were centrifuged at 
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500g for 10 min at 4°C. To remove myelin, cells were suspended in 10 mL of 30% Percoll (GE 
Healthcare) and centrifuged at 700g for 10 min at room temperature without break. The myelin 
layer at the top was removed, and the cell pellet was re-suspended in HBSS + 10%FBS, run 
through a 40-µm cell strainer, and centrifuged at 500g for 10 min at 4°C. The cell pellet was re-
suspended in cold PBS + 2% FBS to perform cell count and FACS staining. Utilized antibodies 
are listed in Table S1. Samples were analyzed on a LSR II flow cytometer with FACSDiva 
software (BD). Compensation and analysis were performed with FlowJo software (TreeStar) and 
gates were defined by fluorescence minus one controls.  
 
 
ULBP3 binding studies 
 
Human peripheral blood mononuclear cells (PBMC) were isolated from whole blood via density 
gradient over Ficoll-Paque 1.077 (FisherScienctific; 45-001-751). Buffy coat layer was isolated, 
cells were washed in 1X PBS twice to remove platelets (300xg). Cells were used fresh or frozen 
at 10-20x106/ml in freeze media (90% FBS, 10% FBS) for later use. Mouse spleens were 
harvested from naïve C57BL/6 mice via mechanical dissociation and filtration over a 70 µm 
filter. Erythrocytes were removed using ACK lysing buffer (FisherScientific; A1049201). Cells 
were used fresh or frozen at 10-20x106/ml in freeze media (90% FBS, 10% FBS) for later use. 
Staining was carried out in 96-well round bottom plates with 1x106 cells/ well. Cells were 
washed and stained in Stain Buffer (BD; 554657) + 2 mM EDTA. Live/dead staining was 
performed using Live/Dead Fixable Yellow Amine Die (Life Technologies; L34968). Fc 
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receptors were blocked to prevent non-specific binding of antibodies or rhULBP3-Fc chimera 
protein (R&D Systems; 1517-UL-50) using TruStain FcX (Biolegend; mouse: 101320, human: 
422302) and following manufacturer’s protocol. Cells were then treated with or without 10 or 20 
µg/ml anti-NKG2D blocking antibody (mouse or human, repsecively) (R&D Systems; human: 
MAB139, mouse: MAB1547) for 20 minutes at RT. Cells were washed then incubated with 
species appropriate flow panels (below) and 5 or 20 µg/ml rhULBP3-Fc (mouse or human, 
respectively) for 20 minutes at RT. Cells were washed and stained with APC anti-human IgG-Fc 
secondary antibody. Finally, cells were washed and resuspended FluorFix fixation buffer 
(Biolegend; 422101). Samples were run on a BD LSR Fortessa, data acquired using FACSDiva 
software (BD), and analyzed using FlowJo Software. 
 
 
In vitro cytotoxicity assay 
 
Early passage, XFM-Luc-derived primary mouse glioblastoma cells were maintained in 
neurobasal medium supplemented with 5 mM Glutamine, 50 ml B27, 20 ng/ml EGF and 10 
ng/ml FGF. Cells were separated utilizing accutase and were seeded at a density of 5.000 per 
well in 200 µl medium in 96-well plates overnight. Subsequently, cells were treated with oHSV 
at indicated log10 increasing doses in quadruplicates for 48 hours. Cell-free medium was utilized 
as a negative control and cells lysed with 1% triton X-100 were the positive control. The 
microplate was then centrifuged at 250 × g for 10 min and 100 µl medium transferred into a 
corresponding flat bottom 96-well plate and 100 µl freshly prepared reaction mixture to each 
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well, incubated for 30 min at room temeperature protected from light, and the absorbance at 490 
nm was measured utilizing standard plate reader. 
 
 
Bioinformatics  
 
RCC files were analyzed with nSolver software. A statistical cutoff of log2 fold change > 1.25 
was used to find differentially regulated genes. Gene ontology (GO) and Kyoto encyclopedia of 
genes and genomes (KEGG) enrichment analysis was done using R Bioconductor Packages 
cluster Profiler v 3.4.4 (36) and dotplots were made using R Bioconductor package DOSE (37) 
and ggplot2 (38). For both GO and KEGG analysis, the gene universe was restricted to the genes 
arrayed in both the panels. 
 
 
Statistical analysis 
 
Statistical analysis was performed using GraphPad prism 7 (GraphPad Software, San Diego, 
CA). Unpaired two-tailed t-test was used unless otherwise indicated. For survival studies, 
Kaplan-Meier curves were compared utilizing the log-rank test. Linear regression or two-way 
analysis of variance (ANOVA) were done to compare groups in dose response and time course 
analyses. P-values below 0.05 were considered statistically significant. 
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Study approval 
 
Animal studies were carried out in accordance with the Guide for the Care and Use of 
Laboratory Animals, as adopted by the U.S. National Institutes of Health. Animal research was 
prospectively approved by the Institutional Animal Care and Use Committee of the Fred 
Hutchinson Cancer Research Center, Seattle, WA (Animal assurance institutional #A3226-01; 
Protocol #50842). 
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Figure legends 
 
Figure 1. XFM-Luc:PDGF,Cre mouse glioblastomas immunologically resemble human 
glioblastoma. A. Representative tumor sections of XFM-Luc:PDGF,Cre glioblastomas (Mouse, M, N=4) 
and human IDH wildtype glioblastoma (Human, Hu, N=4), staining by immunohistochemistry as 
indicated, quantitation of  (i) Cd3+ cells in five 40x high power fields (HPF) per sample, and (ii) of the 
area covered by Iba1+ TAMs (N=4 per group). *, necrosis; scale bar, 200 μm; 2-sided t-test; n.s., not 
significant. B. Flow cytometry of Cd45+ cells in brain hemispheres bearing untreated XFM-
Luc:PDGF,Cre glioblastomas. N=46 tumors from N=8 independent experiments. ****, p<0.001 
(ANOVA). Red bars, myeloid cell population; Mon, monocytes (Cd45high;Cd11b+;Ly6chigh;Ly6g-); Mac, 
macrophages (Cd45high;Cd11b+;Ly6clow;Ly6g-); MG, microglia (Cd45low;Cd11b+;Ly6clow;Ly6g-); PMN, 
polymorphonuclear neutrophils (Cd45high;Cd11b+;Ly6clow;Ly6g+); Cd4+, T-helper cells 
(Cd45+;Cd3+;Cd4+); Cd8+, cytotoxic T-cells (Cd45+;Cd3+;Cd8+); NK, natural killer cells (Cd45+;Cd49+). 
C. Symptom-free survival of mice bearing XFM-Luc:PDGF,Cre glioblastomas treated with isotype 
control or indicated immune checkpoint inhibitory monoclonal antibodies (10 mg/kg i.v. every other day, 
N=5-6 per group). Treatment was initiated on day 14 after tumor initiation. Survival curves were 
compared utilizing the logrank test. 
 
Figure 2. oHSVULBP3 reverts immunologic inertness and prolongs survival of glioblastoma-bearing 
mice. A. Experimental setup. B. Symptom free survival. PBS, N=35; oHSV, N=10; oHSVULBP3, N=36. 
Kaplan-Meier curves were compared utilizing the log rank test. C. Representative H&E staining and 
immunohistochemistry of eGFP in adjacent tissue slides of oHSVULBP3-treated mouse glioblastomas. 
Arrows, localized hypocellular zone (left panel) co-localizing with eGFP+ viral replication (right panel). 
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Scale bar, 2 mm. D. Representative immunohistochemistry stainings of HSV antigens (left panel) and 
Iba1+ TAM (right panel) in oHSVULBP3-treated mouse glioblastomas. Inlay, activated Iba1+ cells. Scale 
bar, 200 μm. E, F. Tumor surface area covered by Iba1+ cells determined by automated image analysis 
(E) and counts of the maximum number of Cd8+ T-cells detected per high power field (HPF, F) in mouse 
glioblastomas 7 days after tumor injection with PBS or 1x106 PFU of indicated oHSVs. N=4 tumors per 
group; two-tailed unpaired t-test, * p<0.05. G. Volcano plot of differentially expressed genes of the 
nCounter myeloid panel in PBS versus oHSVULBP3-treated mouse glioblastomas (N=5 per group, day 7 
after treatment). H. Gene set enrichment analysis of genes up-regulated in oHSVULBP3 (red in panel G).  
 
Figure 3. Localized oHSVULBP3 infection elicits a distant immune response and sensitizes distant 
tumor lesions to anti-Pd1. A. Experimental setup. B. Biolominescence imaging of contralateral, not 
virally treated tumors in indicated treatment groups. N=5-6 mice/group. C. Symptom-free survival. PBS 
co-treated with isotype control (N=19) or anti-Pd1 (N=11); oHSVULBP3 co-treated with isotype control 
(N=20) or anti-Pd1 (N=12). Kaplan-Meier curves were compared utilizing the log rank test. D. Flow 
cytometry normalized histograms depicting the Cd45+ immune cell population in mouse glioblastoma-
bearing hemispheres 7 days after injection with PBS or oHSVULBP3 (left panel), and distant untreated 
hemispheres from the same mice (right panel). E. Cd8+ cell counts in distant hemispheres upon 
unilateral treatment with PBS or oHSVULBP3 in combination with anti-Pd1 or isotype 10 mg/kg i.v. every 
other day. Immunohistochemistry was done on day 7 after initiation of treatment. N=4 mice per group. 
Unpaired, two-tailed t-test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. F. Representative 
immunohistochemistry staining of Cd8+ cells in untreated tumor-bearing hemispheres. Upper panels, 
PBS; lower panels, oHSVULBP3 co-treated with anti-Pd1; Scale bars, 100 μm.  
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Figure 4. Anti-Pd1 augments oHSVULBP3 driven distant TAM activation. Bilateral XFM-
Luc:PDGF,Cre glioblastoma-bearing mice were treated unilaterally as indicated in Figure 3A. A. Flow 
cytometry time-course analysis of the tumor-infiltrating monocyte fraction 
(Cd45+;Cd11b+;Ly6chigh;Ly6g-). N=5-8 mice/group/timepoint; mean +/- standard error; unpaired 2-
tailed t-test, ** p<0.01, *** p<0.001, **** p<0.0001. B. Representative H&E or Iba1 
immunohistochemistry stainings in adjacent slides of untreated hemispheres (distant), contralateral to 
tumors injected with PBS or oHSVULBP3. Green lines, pseudopalisading cells around necrosis; scale bars: 
200 μm. C. Flow cytometry time-course analysis of the TAM fraction (Cd45+;Cd11bhigh;Ly6clow;Ly6g-). 
N=5-8 mice/group/timepoint; mean +/- standard error; unpaired 2-tailed t-test, ** p<0.01, *** p<0.001, 
**** p<0.0001. D. Volcano plot of differentially expressed myeloid genes in distant tumors, contralateral 
to oHSVULBP3 treatment, with versus without co-treatment with anti-Pd1 (N=5 per group). E. Gene set 
enrichment analysis of genes up-regulated in distant tumors upon add-on of anti-Pd1 to oHSVULBP3 
(magenta in panel D).  
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Abstract 
Oncolytic viruses induce local tumor destruction and inflammation. Whether virotherapy can also 
overcome immunosuppression in non-infected tumor areas is under debate. To address this question, we 
have explored immunologic effects of oncolytic herpes simplex viruses (oHSV) in a genetically 
engineered mouse model of IDH wildtype glioblastoma, the most common and most malignant primary 
brain tumor in adults. Our model recapitulates the genomics, the diffuse infiltrative growth pattern, and 
the extensive macrophage-dominant immunosuppression of human glioblastoma. Infection with an 
oHSV that was armed with a ULBP3 expression cassette inhibited distant tumor growth in the absence of 
viral spreading (abscopal effect) and yielded accumulation of activated macrophages and T-cells. There 
was also abscopal synergism of oHSVULBP3 with anti-Pd1 against distant, uninfected tumor areas, albeit 
consistent with clinical trials in glioblastoma patients, monotherapy with anti-Pd1 was ineffective in our 
model. Arming oHSV with ULBP3 led to up-regulation of antigen processing and presentation genesets 
in myeloid cells. The cognate ULBP3 receptor NKG2D is however not present on myeloid cells, 
suggesting a non-canonical mechanism of action of ULBP3. Overall, the myeloid-dominant, anti-Pd1-
sensitive abscopal effect of oHSVULBP3 warrants further investigation in patients with IDH wildtype 
glioblastoma. 
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Introduction 
Glioblastoma, the most common primary malignant brain cancer in adults, is an invariably 
deadly disease with median overall survival in the range of 12 months (1). The advent of 
immunotherapy prompted a plethora of clinical trials seeking to overcome the distinctive 
immunosuppression of these tumors, but phase III immunotherapy clinical trials of various 
strategies in glioblastoma patients have failed to prolong survival (2). The tumor 
microenvironment of glioblastoma is dominated by immunosuppressive tumor-associated 
microglia and macrophages (TAM) that limit immune surveillance by lymphocytes (3).  
 
Preclinical exploration of microenvironment modulating therapies requires bona fide cancer 
models with histologic and immunologic features that resemble their human counterparts as 
closely as possible. Applying a sequential bioinformatics and genetic engineering approach to 
identify and subsequently model relevant oncogenic events, we have previously generated mouse 
glioblastoma models that develop in situ from the mice’s own cells and that are histologically 
and molecularly highly similar to human glioblastoma (4).  
 
Promising response rates and translational data from early phase biological endpoint trials 
support the rationale and feasibility of virotherapy approaches to revert immunosuppression in 
glioblastoma (5-7). Oncolytic viruses are usually administered locally, either directly into the 
tumor, or into the resection cavity during surgery. In order to be efficacious in patients with 
disseminated tumors or multifocal cancer, virotherapy will however need to induce distant anti-
cancer immune responses beyond local tumor cell lysis.  
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Here, we explored localized and distant (abscopal) immunologic effects of oncolytic virotherapy 
in a genetically engineered, immunologically inert model of diffusely infiltrating glioblastoma. 
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Results 
 
Immunologic properties of genetically engineered IDH wildtype glioblastoma  
 
The vast majority of glioblastomas are classified by the lack of IDH mutations and harbor gain of 
chromosome 7, loss of heterozygosity of chromosome 10 and homozygous deletion of CDKN2A 
(4, 8)(Figure S1A). We have utilized the RCAS/tv-a gene transfer system in N/tv-a;Cdkn2a-/-
;Ptenfl/fl;LucLSL/LSL (XFM-Luc) mice to generate IDH wildtype glioblastomas in situ from the 
mice’s own cells. Nestin-positive neural stem- and progenitor cells in XFM-Luc mice were 
infected with RCAS-PDGF to model chromosome 7 gain, and with RCAS-Cre to model loss of 
chromosome 10 (XFM-Luc:PDGF,Cre) (4)(Figure S1B).  
 
Immunohistochemistry of mouse and human IDH wildtype glioblastomas suggested that key 
components of the immune cell compartment are similar between our genetically engineered 
mouse glioblastomas and their human counterparts. There was a vast abundance of Iba1+ TAMs, 
which accumulated in zones of pseudopalisading necrosis, whereas Cd3+ tumor-infiltrating 
lymphocytes were hardly detected (Figure 1A). Flow cytometry confirmed that XFM-
Luc:PDGF,Cre glioblastomas have few if any lymphocytes and that the majority of Cd45+ cells 
were of myeloid origin, predominantly comprising bone-marrow derived macrophages 
(Cd45high;Cd11b+;Ly6clow;Ly6g-, mean 53%, Figure 1B). Consistent with the only completed 
phase III clinical trial of immune checkpoint inhibition in patients with glioblastoma (9), various 
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immune checkpoint inhibitors had no effect on the survival of XFM-Luc glioblastoma-bearing 
mice (Figure 1C). 
 
Our model reflects the immune phenotype of its human counterpart (3) and circumvents major 
limitations of commonly utilized syngeneic cancer models, including hypermutation, lymphocyte 
accumulation and an inherent response to immune checkpoint inhibition (10, 11).  
 
 
oHSVULBP3 leverages accumulation of activated TAMs 
 
We have utilized this IDH wildtype glioblastoma model as a paradigm to develop an oHSV, 
which we optimized for the treatment of glioblastoma utilizing a miR-124-based attenuation 
strategy (12) (Figure S2A-E, Note S1). Moreover, as a means to augment an expected 
virotherapy-induced immune response, we generated an oHSV, which included a payload 
cassette to drive the expression of human UL16-binding protein 3 (ULBP3), a class 1 major 
histocompatibility complex (MHC)-like molecule and member of the family of ligands of the 
killer cell lectin-like receptor subfamily K member 1 (NKG2D). NKG2D-independent pro-
inflammatory effects on myeloid cells have been reported for ULBP3, but not for ULBP1 or 
ULBP2 (13), rendering ULBP3 our prime candidate payload to revert the macrophage-dominant 
immunosuppression of glioblastoma. 
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Mice bearing XFM-Luc:PDGF,Cre glioblastomas were randomized to undergo intratumoral 
injection of PBS, oHSV or oHSVULBP3 (Figure 2A). oHSVULBP3 prolonged median survival after 
treatment from 8 to 18 days (hazard ratio [HR] 0.28, p<0.001) and inhibited tumor growth as 
assessed by luminescence imaging (p=0.013), whereas oHSV lacking the ULBP3 payload 
cassette did not (HR 1.02, p=0.94, Figure 2B, Figure S2F). Therefore, we focused our further 
efforts on oHSVULBP3 to determine its utility as an investigational new drug.  
 
Histopathological analysis of glioblastoma-bearing mice sacrificed on day 7 after intratumoral 
injection of oHSVULBP3 revealed necrotic areas in zones of viral replication in 4 of 4 analyzed 
mice indicating oncolysis (Figure 2C). Viral replication and oncolysis were generally restricted 
to small foci surrounding the injection site. Immunohistochemistry staining identified 
accumulation of Iba1+ myeloid cells in eGFP+ zones of oHSVULBP3 replication (Figure 2D). 
Computed imaging analyses of Iba1-stained tumor sections (N=4 per group, day 7 after viral 
infection) revealed that upon treatment with oHSVULBP3 the overall tumor area covered with 
Iba1+ cells increased by >2-fold compared to PBS-injected tumors (p=0.016), but oHSV lacking 
the ULBP3 expression cassette did not have that effect (p=0.66, Figure 2E).  
 
 
oHSVULBP3 leverages accumulation of activated T cells 
 
We have considered adding ULBP3 primarily to strengthen oHSV-induced anti-viral T-cell 
responses, because its cognate human receptor NKG2D amplifies the cytotoxicity of activated T-
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cells in addition to activating NK-cells (14). There was indeed an increase in Cd8+ T-cells in 
oHSVULBP3-treated tumors (mean Cd8+ cells per HPF in PBS vs oHSVULBP3 = 2 vs 19, N=4 per 
group, p=0.015), but not in tumors treated with an oHSV that was lacking ULBP3 (p=0.14, 
Figure 2F). The number of tumor-infiltrating FoxP3+ regulatory T-cells increased from 1 to 7 
per HPF upon treatment with oHSVULBP3 (p=0.018), but the ratio of Cd8+/FoxP3+ increased 
from 2 to 3 (p=0.020, Figure S2G). oHSVULBP3-driven Cd8+ T-cell influx was further enhanced 
by co-treatment with anti-Pd1 (p=0.003), but anti-Pd1 had no effect on Cd8+-influx in the 
absence of virotherapy (p=0.55, Figure S2H). There was also synergism of oHSVULBP3 and anti-
Pd1 in promoting the Cd8+;Cd44-;Cd62L- effector T-cell phenotype from 1% in PBS-treated 
tumors to 15% of Cd8+ cells in oHSVULBP3 plus anti-Pd1 co-treated tumors (p=0.002). 
Interestingly, both treatments given as mono-therapy had only minor effects on the effector T-
cell fraction (Figure S2I). By contrast, flow cytometry determined only a minor increase in NK-
cells on day 7 after treatment with oHSVULBP3 (p=0.026, Figure S2J). This increase was 
accompanied by a decrease in Cd69+ activated NK-cells (p=0.036, Figure S2K) and loss of 
Nkg2d (% Nkg2d+ of  NK-cells upon treatment with PBS vs oHSVULBP3 = 21 vs 3, p<0.001, 
Figure S2L), indicating that NK-cells were likely not the driving force of the observed survival 
benefit. 
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oHSVULBP3 promotes antigen presentation and toll-like receptor signaling 
 
In order to characterize the effects of oHSVULBP3 on the tumor microenvironment in more detail, 
we performed nCounter gene expression analyses utilizing two gene panels, myeloid innate 
immunity and immunology (N=5 tumors per group and panel).  Within the myeloid innate 
immunity gene panel (N=732 genes), there were N=461 genes that were >2-fold upregulated and 
N=10 genes that were >2-fold downregulated in tumors injected with oHSVULBP3 versus PBS 
(Figure 2G). Geneset enrichment analysis of genes up-regulated upon oHSVULBP3 treatment 
versus PBS identified the gene ontology (GO) terms antigen presentation (p=0.002) and toll-like 
receptor (TLR) signaling (p=0.002, Figure 2H). Both genesets were also upregulated in tumors 
treated with oHSVULBP3 versus oHSV (antigen presentation, p=0.043; TLR signaling, p=0.043), 
suggesting a ULBP3-mediated effect. Similar analyses of the immunology gene panel (N=545 
genes) in tumor-bearing mice treated with oHSVULBP3 versus PBS identified enrichment of the 
Kyoto encyclopedia of genes and genomes (Kegg) genesets phagosome (p=0.023) and confirmed 
enrichment of antigen processing and presentation (p=0.004) as well as a trend for increased 
TLR signaling (p=0.065) upon oHSVULBP3 treatment (Figure S2M).  
 
The dominance of a myeloid immune response was surprising in the light of putative NKG2D-
mediated effects of ULBP3. Since the cognate ULBP3 receptor Nkg2d is not present on myeloid 
cells, we assume a non-canonical mechanism of action of ULBP3. A previous study utilizing the 
EL4 and RMA mouse tumor models demonstrated that ectopic expression of human ULBP3 in 
murine tumor cells results in tumor rejection, but failed to demonstrate binding of ULBP3 to 
murine Nkg2d (13). Structure interaction modeling utilizing the protein modeling portal (15) 
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predicted a weak, if any, physical interaction of human ULBP3 with human NKG2D, and 
suggested that human ULBP3 did not bind to the mouse orthologue of NKG2D (Figure S2N). 
Flow cytometry of human peripheral blood mononuclear cells and murine splenocytes utilizing 
Fc-tagged recombinant ULBP3 confirmed binding of ULBP3 to NKG2D-negative myeloid cells; 
pretreatment with NKG2D blocking antibodies did not abrogate ULBP3 binding to myeloid cells 
(Figure S2O). Collectively, these data suggest a non-canonical mechanism of action of ULBP3 
that drives antigen processing and presentation through interaction with an unknown receptor on 
myeloid cells. This notion is supported by publically available data from mass spectrometry 
based affinity capture experiments in human cell lines, which identified 19 ULBP3 binding 
partners (16) which are also enriched for the GO term antigen processing and presentation 
(Figure S2P). In humans, ULBP3 is in addition a cognate ligand of NKG2D, suggesting that in 
patients, oHSVULBP3 may exert additional favorable immune modulating effects through 
activation of NK and T cells via NKG2D. 
 
 However, while our study supports a model of pleiotropic effects of ULBP3, anti-tumor activity 
could also result from the generation of opsonizing antibodies directed against soluble Nkg2d 
ligands (17). More in-depth research will be required to determine the precise mechanism by 
which ULBP3 activates macrophages. 
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Abscopal accumulation of activated T-cells upon localized oHSVULBP3 infection  
 
We reasoned that virotherapy could only be effective against metastasizing or diffusely 
infiltrating cancers such as glioblastoma if an anti-cancer immune response was elicited not only 
locally, but also distant from the site of tumor infection, i.e. by exerting an abscopal effect. In 
order to model oHSV-infected and uninfected tumor portions, we generated to spatially 
segregated tumors in both hemispheres of XFM-Luc mice. In this modified bilateral 
glioblastoma model, luciferase was activated only in the untreated tumor portion (Figure S3A), 
allowing to monitor abscopal growth independent of local effects of virotherapy.  
 
We then utilized this model to explore abscopal effects of localized oHSVULBP3 therapy (Figure 
3A). Unilateral treatment with oHSVULBP3 inhibited contralateral tumor growth (Figure 3B) and 
prolonged survival (HR 0.49, p=0.003, Figure 3C). Of note, contralateral, Luc+ tumor lesions 
were survival-limiting (Figure S3B)(4), indicating that the survival benefit from unilateral 
treatment was due to abscopal inhibition of tumor growth. The lack of any survival effect of 
oHSV without the ULBP3 expression cassette (Figure 2) and the lack of viral replication in 
normal brain cells (Note S1) suggested that infection and replication of oHSVULBP3 in the tumor 
was a prerequisite for inducing an abscopal effect. There was also abscopal sensitization to 
immune checkpoint inhibition with anti-Pd1, which translated into prolonged survival among 
those mice that survived for at least 7 days (HR 0.31, p=0.014, N=5-6 mice per treatment arm, 
Figures 3C and S3C).  
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Flow cytometry of paired oHSVULBP3-treated and contralateral untreated tumor areas (XFM-
Luc:PDGF,Cre) determined a bilateral >2-fold increase of the Cd45+ bone marrow-derived 
immune cell fraction 7 days after virotherapy (Figure 3D). Utilizing a customized nCounter high-
sensitivity gene expression array, the detection of viral RNA was locally restricted to treated 
tumors (Figure S3D), thus precluding that viral spread caused the abscopal accumulation of 
Cd45+ cells. 
 
There was abscopal T-cell memory formation, activation and exhaustion. By day 3 after 
unilateral oHSVULBP3 treatment, there was a bilateral induction of Cd44+;Cd62L+ central 
memory T-cells in both the Cd4+ and Cd8+ tumor-infiltrating lymphocyte fractions (Figure 
S3E), suggesting that the abscopal effect involves T-cell memory. The fraction of Cd8+ tumor-
infiltrating lymphocytes positive for the activation markers Cd69 or Nkg2d increased 
simultaneously in virus-treated tumors and abscopally in 5 of 5 mice (Figure S3F). By contrast, 
the Cd8+;Cd44-;Cd62L+ naïve lymphocyte fraction was almost completely suppressed 
bilaterally (Figure S3G). The rationale for combining oHSVULBP3 with anti-Pd1 was further 
supported by a 3-fold increase in the fraction of Pd1+;Tim3+ exhausted Cd8+ T-cells in 
oHSVULBP3 treated tumors (8 of 8 analyzed tumors, p<0.001), and a >1.5-fold abscopal increase 
(6 of 8, p=0.022, Figure S3H). 
 
Immunohistochemistry of untreated contralateral tumors also revealed an abscopal increase in 
total infiltrating Cd8+ T-cells upon ipsilateral oHSVULBP3 treatment in 2 of 4 analyzed tumors 
(p=0.13), and this trend was further augmented to a mean 12-fold increase in abscopal Cd8+ 
tumor infiltration upon co-treatment with anti-Pd1 (p=0.003, Figure 3E). In line with flow 
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cytometry findings, the morphological notion of an enlarged cytoplasm and vesicles 
accumulating at the cellular membrane were suggestive of an activated state of these Cd8+ cells 
(Figure 3F). In summary, these data indicate that oHSVULBP3 initiates an abscopal T-cell 
response that can be augmented utilizing immune checkpoint inhibition with anti-Pd1. 
 
 
Abscopal TAM accumulation and activation upon localized oHSVULBP3 infection 
 
Since the model used here does not contain known non-synonymous mutations, it remains 
elusive which (neo-)antigens could have triggered bilateral accumulation and activation of T-
cells upon unilateral oHSVULBP3 treatment. Human glioblastoma likewise carries only few non-
synonymous mutations (18), but naturally occurring T-cell responses directed against tumor-
associated antigens of development-associated genes have been reported (19). Whether similar 
antigens elicit T-cell responses in mouse glioblastomas is not known. In fact, the observed 
bilateral influx of activated T-cells could have been an epiphenomenon of a unilateral T-cell 
response against HSV antigens or against ULBP3, which is a foreign antigen in the mouse too, 
followed by surveillance of the entire brain. This possibility indicates that direct killing of tumor 
cells by macrophages could account for the majority of the observed anti-tumor effect of 
oHSVULBP3, at least in untreated tumor lesions where viral replication did not occur and where 
therefore foreign antigens were not present. 
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To explore this possibility, we sought to characterize the oHSVULBP3-driven myeloid immune 
cell infiltrate in more detail. We did time course analyses of tumor-infiltrating Cd45+ cells by 
flow cytometry of oHSVULBP3-treated tumors and contralateral untreated tumors in the bilateral 
XFM-Luc:PDGF,Cre glioblastoma model. There was an early bilateral influx of monocytes 
(Cd45+;Cd11b+;Ly6c+) in 8 of 8 mice peaking at day 3 after virotherapy in both, ipsilateral, 
treated tumors (>5-fold, p<0.001), and abscopally (>4-fold, p<0.001, Figure 4A). 
Immunohistochemistry for Iba1 confirmed an abscopal increase of TAM (1.5-fold, p=0.014) in 4 
of 4 analyzed tumors upon unilateral oHSVULBP3 treatment, and anti-Pd1 treatment further 
augmented that abscopal effect in 2 of 4 untreated tumors (p=0.040), although we noted no effect 
of anti-Pd1 monotherapy on TAM accumulation (p=0.90, Figure S4A). Interestingly, 
immunohistochemistry also revealed that ipsilateral treatment with oHSVULBP3 yielded abscopal 
relative exclusion of Iba1+ TAMs from pseudopalisades and transformation towards a phenotype 
suggestive of phagocytosis and potentially pro-inflammatory activation (Figure 4B). In line with 
the notion of bilateral macrophage activation upon unilateral treatment with oHSVULBP3, flow 
cytometry determined a bilateral >3-fold bilateral increase in cells expressing the macrophage 
activity marker Cd44, which persisted by day 14 after unilateral oHSVULBP3 infection (Figure 
S4B). There was also upregulation of MHC-II molecules on the cell surface of Cd11c+;MHC-II+ 
cells upon oHSVUBLP3 treatment both, ipsilaterally (p=0.007) in 7 of 7, and in 6 of 7 contralateral 
untreated tumors (p=0.011, Figure S4C). Gene expression analyses of tumors contralateral to 
oHSVULBP3-treatment were also suggestive of pro-inflammatory TAM repolarization, including a 
>4-fold increase of the Cd68/Cd163 ratio (p=0.005, Figure S4D), and up-regulation of MAPK 
signaling (p=0.003) and NFκB signaling (p=0.003, Figure S4E).  
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TAM activation yields up-regulation of the immune checkpoint receptor Pd1, and activation of 
Pd1 by its main ligand Pdl1 drives immunosuppressive repolarization of TAM (20).  Flow 
cytometry of bilateral XFM-Luc:PDGF,Cre glioblastomas determined Pd1 on more than 70% of 
TAM in both, oHSVULBP3 treated tumors and abscopally, compared to approximately 20% Pd1+ 
TAM in PBS-treated tumors (Figure 4C). As an add-on to virotherapy, anti-Pd1 treatment was 
also associated with enrichment of the antigen presentation geneset in both oHSVULBP3 treated 
tumor lesions (p=0.037) and abscopally in untreated tumor areas (p=0.017, Figure 4D,E).  
Upon treatment with anti-Pd1 alone (10 mg/kg i.v. every other day), nCounter gene expression 
analysis (5 mice/group) of a myeloid innate immunity panel determined enrichment GO terms 
associated with pro-inflammatory processes, including antigen presentation (p<0.001), interferon 
signaling (p<0.001) and TLR signaling (p=0.012, Figure S4F). Similar enrichment patterns could 
be determined by Kegg geneset enrichment analysis (Figure S4G). 
Similar analyses applying the nCounter immunology gene panel identified abscopal enrichment 
of the KEGG genesets phagosome (p=0.008) and TLR signaling (p=0.032) when anti-Pd1 was 
added to oHSVULBP3. These data indicate that combination with anti-Pd1 augments TAM-driven 
local and abscopal effects of oHSVULBP3.  
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Discussion 
 
Oncolytic virotherapy has emerged as a viable approach to revert immunosuppression in 
immunologically “cold” cancers, including glioblastoma (2, 5-7, 21-29). Here, we have 
employed a miR-124-based oHSV attenuation system that circumvents interferon sensitivity 
conveyed by the commonly utilized ICP-34.5 loss of function attenuation strategy (12). Arming 
our miR-124-attenuated oHSV with ULBP3 promoted a localized and abscopal anti-cancer 
immune response and sensitized to anti-Pd1 in a clinically relevant genetic glioblastoma model 
(4). 
 
The notion of direct tumor cell killing by activated macrophages is consistent with pre-clinical 
reports in other entities, e.g. non-hypermutated colon cancer (30). Moreover, the pro-
inflammatory effect of anti-Pd1 on myeloid cells in virus-injected and distant, untreated tumor 
areas underscores the role of Pd1-signaling as an inhibitory pathway in tumor-macrophages (20) 
and supports combination treatments of oHSV with anti-Pd1 irrespective of tumor T-cell 
infiltration.  
 
Extensive TAM infiltration and activation followed by an adaptive immune response following 
virotherapy has been reported previously, including in syngeneic glioblastoma models (27, 31). 
Beyond the necessity of macrophage repolarization for establishing an adaptive immune 
response, our data also support previous reports on the role of TAM for the clearance of oHSV-
infected cells (32, 33). Similar effects of NK-cells have also been reported to limit the efficacy of 
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oHSV treatment (34), albeit in our model down-regulation of activation markers and the low 
abundance of NK-cells suggest that mainly TAM have limited viral spreading.  
 
A previous report on the combination treatment of an oHSV with immune checkpoint inhibition 
in a therapeutically challenging immune-suppressed glioblastoma model demonstrated that 
TAMs and T-cells are both required to exert efficacious anti-tumor effects (27). The observed 
dominance of a myeloid immune response in our model may have several reasons: (i) gene 
expression changes in the lymphocytic compartment were likely covered by myeloid- and tumor-
associated gene expression patterns due to the relatively lower abundance of lymphocytes. (ii) 
Our genetic in situ modeling approach does not convey potentially immunogenic neo-antigens, 
thus likely limiting the efficacy of T-cell infiltration. (iii) The short survival time of our model 
may not suffice to fully establish an anti-cancer T-cell response, i.e. the observed infiltration of 
activated T-cells may be no more than the onset of such a response. Therefore, depleting 
macrophages (e.g. utilizing clodronate liposomes) will likely have a more prominent effect than 
depleting Cd8 T-cells in our model, but the translational relevance of such findings will be 
limited by the above-mentioned characteristics of our model. 
 
Yet, our model also conveys major advantages over commonly utilized syngeneic glioblastoma 
models, including (i) the omission of cell culture artifacts by inducing tumors in situ from the 
mice’s own cells, (ii) the presence of oncogenic driver events that are indeed present in human 
glioblastoma (versus random oncogenic transformation by chemical induction or ex vivo 
overexpression of oncogenes that are rare in glioblastoma, e.g. mutated RAS), and (iii) a 
distinctive lymphocyte depletion in untreated tumors.  
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In summary, the herein presented data support further development of virotherapy as a means to 
sensitize cancers to immune checkpoint inhibition, including in diffusely infiltrating brain 
cancers where only a subset of cells can be infected. 
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Methods 
 
Genetically engineered mouse glioblastoma model 
 
All animal experiments were done in accordance with guidelines from the Institutional Animal 
Care and Use Committees of Fred Hutchinson Cancer Research Center. The RCAS/Tva model 
system was used to generated mouse glioblastomas (35). N/tva; Cdkn2a/b-/-; Ptenflox/flox; LSL 
Luciferase mice were used as genetic backgrounds for RCAS mediated glioblastoma formation. 
For a bilateral tumor model, following introduction of RCAS-PDGFB with RCAS-Cre into one 
hemisphere and RCAS-PDGFB with RCAS-shPten into the contralateral hemisphere for 
bioluminescence, two genetically similar tumors are present where one tumor lacks luciferase 
expression (PDGFB/shPten; treated glioblastoma) and another tumor with luciferase expression 
(PDGFB/Pten-/- Luciferase; distant glioblastoma for assessment of abscopal response). Tumors 
were generated in 4-6-week-old male and female adult mice injected with 2x105 DF1 cells 
delivered with a 30-gauge needle attached to a Hamilton syringe and stereotactic fixation device 
(Stoelting, Wood Dale, IL). Cells were injected into the frontal cortex of each hemisphere: 
Coordinates were lateral to bregma 3mm at a depth of 1mm. Treatment began 14 days after 
tumor formation.  
The RCAS vectors used were generated as previously described (4). Briefly, DF1 cells were 
purchased from ATCC and grown at 39ºC. Transfections with RCAS vectors were performed 
using the Fugene 6 transfection kit (Roche E2691). Nestin-specific, Cre-recombinase responsive 
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PDGF-luciferase expressing mouse models were monitored until they developed signs of tumor 
burden including lethargy, poor grooming, weight loss, macrocephaly, seizure and paralysis.  
 
 
Virotherapy and drug treatments in vivo 
 
Adult mice were sedated with isoflurane. The same coordinates as for tumor initiation were 
utilized for oncolytic virus treatment. Injection of 106 PFU of indicated oHSV strains in 1 µl 
PBS, or 1 µl PBS alone, were injected over 2 minutes utilizing a 30 gauge needle attached to a 
Hamilton syringe and stereotactic fixation device. In the double-tumor model, only one tumor 
was injected. The same stereotactic coordinates as for tumor formation were utilized.  
Endotoxin low (≤0.001 EU/µg; ≤ 1 EU/mg) anti-Ctla4, anti-Pdl1, anti-Pd1, or indicated isotype 
controls (10µg/g mouse body weight, see Table S1) were administered starting on the day of 
virotherapy and then every other day until endpoint. Bioluminescence signals were obtained for 
each treatment group every 2-3 days following treatment. The last bioluminescence signal 
represents the last time point measured prior to reaching end-point (See Kaplan-Meier curve for 
end-points). Animals were sacrificed upon development of neurological symptoms as defined by 
the Institutional Animal Care and Use Committee.  
 
 
 
 22 
Bioluminescence  
 
Bioluminescence imaging was obtained on the Xenogen IVIS 100 system. Mice with tumors 
expressing luciferase were anesthetized with isofluorane before retroorbital injection with 
75mg/kg body weight D-luciferin (Caliper Life Sciences Part Number #119222). Promptly after 
injection, repeat images were acquired for 3-5 minutes to ensure that the plateau phase of photon 
emission was reached. Total flux (photons seconds-1) was obtained from each mouse.  
 
 
Immunohistochemistry and immunofluorescence 
 
Mouse brains were fixed in formalin and embedded in paraffin, then sectioned at 5mm and 
stained by routine hematoxylin and eosin (H&E), as well as immunohistochemistry (IHC) or 
immunofluorescence (IF). Automated IHC and antigen retrieval for IF was performed on the 
Discovery XT (Ventana Medical Systems Inc.) according the manufacturers standard protocol. 
For IF, after washing with TBS, a blocking step with TBS containing 10% donkey serum of 1 
hour, sections were rinsed with TBS and incubated in a mixture of indicated antibodies of each 
series in TBS containing 2% bovine serum albumine overnight at 4°C. After washing in TBS, a 
cocktail of indicated secondary antibodies was applied for 4 hours at room temperature. Sections 
were washed again, mounted and coverslipped in polyvinyl alcohol with diazabicyclo-octane 
(DABCO) as an anti-fading agent. Images were acquired using a Zeiss LSM 780 NLO confocal 
microscope.  
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Gene expression analysis 
 
Paraffin embedded tissue sections were macro dissected and RNA extracted utilizing the RNeasy  
FFPE kit (Qiagen; 73504). Contaminating DNA was removed with DNase (Thermo Fisher; 
EN0525). 50ng of total RNA was hybridized at 96°C overnight with the nCounter mouse 
immunology and myeloid innate immunity panels (NanoString; XT-CSO-MIM1-12, XT-CSO-
MMII2-12). Hybridized samples were analyzed for frequency of each RNA species using the 
nCounter SPRINT™ profiler (NanoString). Raw mRNA abundance frequencies were analyzed 
using the nSolver™ analysis software 2.5 pack. Normalization factors were derived from the 
geometric mean of housekeeping genes, after QC with built in negative and positive controls.  
 
 
Flow cytometry 
 
Animals were sacrificed, and their brains were removed from the skull immediately after cardiac 
perfusion with 10 mL of ice cold PBS. Mouse brains were mechanically dissociated and gently 
forced through a 70-µm strainer followed by rinsing with 50 mL of Hank's balanced salt solution 
(HBSS) + 10% fetal bovine serum (FBS). Cells were pelleted by centrifugation (500g for 10 min 
at 4°C) and suspended in red blood cell (RBC) lysis buffer (5 mL per brain, 1 min on ice). RBC 
lysis was quenched by adding 3 volumes of HBSS + 10% FBS, and cells were centrifuged at 
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500g for 10 min at 4°C. To remove myelin, cells were suspended in 10 mL of 30% Percoll (GE 
Healthcare) and centrifuged at 700g for 10 min at room temperature without break. The myelin 
layer at the top was removed, and the cell pellet was re-suspended in HBSS + 10%FBS, run 
through a 40-µm cell strainer, and centrifuged at 500g for 10 min at 4°C. The cell pellet was re-
suspended in cold PBS + 2% FBS to perform cell count and FACS staining. Utilized antibodies 
are listed in Table S1. Samples were analyzed on a LSR II flow cytometer with FACSDiva 
software (BD). Compensation and analysis were performed with FlowJo software (TreeStar) and 
gates were defined by fluorescence minus one controls.  
 
 
ULBP3 binding studies 
 
Human peripheral blood mononuclear cells (PBMC) were isolated from whole blood via density 
gradient over Ficoll-Paque 1.077 (FisherScienctific; 45-001-751). Buffy coat layer was isolated, 
cells were washed in 1X PBS twice to remove platelets (300xg). Cells were used fresh or frozen 
at 10-20x106/ml in freeze media (90% FBS, 10% FBS) for later use. Mouse spleens were 
harvested from naïve C57BL/6 mice via mechanical dissociation and filtration over a 70 µm 
filter. Erythrocytes were removed using ACK lysing buffer (FisherScientific; A1049201). Cells 
were used fresh or frozen at 10-20x106/ml in freeze media (90% FBS, 10% FBS) for later use. 
Staining was carried out in 96-well round bottom plates with 1x106 cells/ well. Cells were 
washed and stained in Stain Buffer (BD; 554657) + 2 mM EDTA. Live/dead staining was 
performed using Live/Dead Fixable Yellow Amine Die (Life Technologies; L34968). Fc 
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receptors were blocked to prevent non-specific binding of antibodies or rhULBP3-Fc chimera 
protein (R&D Systems; 1517-UL-50) using TruStain FcX (Biolegend; mouse: 101320, human: 
422302) and following manufacturer’s protocol. Cells were then treated with or without 10 or 20 
µg/ml anti-NKG2D blocking antibody (mouse or human, repsecively) (R&D Systems; human: 
MAB139, mouse: MAB1547) for 20 minutes at RT. Cells were washed then incubated with 
species appropriate flow panels (below) and 5 or 20 µg/ml rhULBP3-Fc (mouse or human, 
respectively) for 20 minutes at RT. Cells were washed and stained with APC anti-human IgG-Fc 
secondary antibody. Finally, cells were washed and resuspended FluorFix fixation buffer 
(Biolegend; 422101). Samples were run on a BD LSR Fortessa, data acquired using FACSDiva 
software (BD), and analyzed using FlowJo Software. 
 
 
In vitro cytotoxicity assay 
 
Early passage, XFM-Luc-derived primary mouse glioblastoma cells were maintained in 
neurobasal medium supplemented with 5 mM Glutamine, 50 ml B27, 20 ng/ml EGF and 10 
ng/ml FGF. Cells were separated utilizing accutase and were seeded at a density of 5.000 per 
well in 200 µl medium in 96-well plates overnight. Subsequently, cells were treated with oHSV 
at indicated log10 increasing doses in quadruplicates for 48 hours. Cell-free medium was utilized 
as a negative control and cells lysed with 1% triton X-100 were the positive control. The 
microplate was then centrifuged at 250 × g for 10 min and 100 µl medium transferred into a 
corresponding flat bottom 96-well plate and 100 µl freshly prepared reaction mixture to each 
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well, incubated for 30 min at room temeperature protected from light, and the absorbance at 490 
nm was measured utilizing standard plate reader. 
 
 
Bioinformatics  
 
RCC files were analyzed with nSolver software. A statistical cutoff of log2 fold change > 1.25 
was used to find differentially regulated genes. Gene ontology (GO) and Kyoto encyclopedia of 
genes and genomes (KEGG) enrichment analysis was done using R Bioconductor Packages 
cluster Profiler v 3.4.4 (36) and dotplots were made using R Bioconductor package DOSE (37) 
and ggplot2 (38). For both GO and KEGG analysis, the gene universe was restricted to the genes 
arrayed in both the panels. 
 
 
Statistical analysis 
 
Statistical analysis was performed using GraphPad prism 7 (GraphPad Software, San Diego, 
CA). Unpaired two-tailed t-test was used unless otherwise indicated. For survival studies, 
Kaplan-Meier curves were compared utilizing the log-rank test. Linear regression or two-way 
analysis of variance (ANOVA) were done to compare groups in dose response and time course 
analyses. P-values below 0.05 were considered statistically significant. 
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Study approval 
 
Animal studies were carried out in accordance with the Guide for the Care and Use of 
Laboratory Animals, as adopted by the U.S. National Institutes of Health. Animal research was 
prospectively approved by the Institutional Animal Care and Use Committee of the Fred 
Hutchinson Cancer Research Center, Seattle, WA (Animal assurance institutional #A3226-01; 
Protocol #50842). 
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Figure 1. XFM-Luc:PDGF,Cre mouse glioblastomas immunologically resemble human glioblastoma. A. Representative 
tumor sections of XFM-Luc:PDGF,Cre glioblastomas (Mouse, M, N=4) and human IDH wildtype glioblastoma (Human, Hu, 
N=4), staining by immunohistochemistry as indicated, quantitation of  (i) Cd3+ cells in five 40x high power fields (HPF) per 
sample, and (ii) of the area covered by Iba1+ TAMs (N=4 per group). *, necrosis; scale bar, 200 μm; 2-sided t-test; n.s., not 
significant. B. Flow cytometry of Cd45+ cells in brain hemispheres bearing untreated XFM-Luc:PDGF,Cre glioblastomas. 
N=46 tumors from N=8 independent experiments. ****, p<0.001 (ANOVA). Red bars, myeloid cell population; Mon, 
monocytes (Cd45high;Cd11b+;Ly6chigh;Ly6g-); Mac, macrophages (Cd45high;Cd11b+;Ly6clow;Ly6g-); MG, microglia 
(Cd45low;Cd11b+;Ly6clow;Ly6g-); PMN, polymorphonuclear neutrophils (Cd45high;Cd11b+;Ly6clow;Ly6g+); Cd4+, T-helper 
cells (Cd45+;Cd3+;Cd4+); Cd8+, cytotoxic T-cells (Cd45+;Cd3+;Cd8+); NK, natural killer cells (Cd45+;Cd49+). C. Symptom-
free survival of mice bearing XFM-Luc:PDGF,Cre glioblastomas treated with isotype control or indicated immune checkpoint 
inhibitory monoclonal antibodies (10 mg/kg i.v. every other day, N=5-6 per group). Treatment was initiated on day 14 after 
tumor initiation. Survival curves were compared utilizing the logrank test. 
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Figure 2. oHSVULBP3 reverts immunologic inertness and prolongs survival of glioblastoma-bearing mice. A. 
Experimental setup. B. Symptom free survival. PBS, N=35; oHSV, N=10; oHSVULBP3, N=36. Kaplan-Meier curves were 
compared utilizing the log rank test. C. Representative H&E staining and immunohistochemistry of eGFP in adjacent tissue 
slides of oHSVULBP3-treated mouse glioblastomas. Arrows, localized hypocellular zone (left panel) co-localizing with eGFP+ 
viral replication (right panel). Scale bar, 2 mm. D. Representative immunohistochemistry stainings of HSV antigens (left 
panel) and Iba1+ TAM (right panel) in oHSVULBP3-treated mouse glioblastomas. Inlay, activated Iba1+ cells. Scale bar, 200 
μm. E, F. Tumor surface area covered by Iba1+ cells determined by automated image analysis (E) and counts of the 
maximum number of Cd8+ T-cells detected per high power field (HPF, F) in mouse glioblastomas 7 days after tumor injection 
with PBS or 1x106 PFU of indicated oHSVs. N=4 tumors per group; two-tailed unpaired t-test, * p<0.05. G. Volcano plot of 
differentially expressed genes of the nCounter myeloid panel in PBS versus oHSVULBP3-treated mouse glioblastomas (N=5 per 
group, day 7 after treatment). H. Gene set enrichment analysis of genes up-regulated in oHSVULBP3 (red in panel G).  
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Figure 3. Localized oHSVULBP3 infection elicits a distant immune response and sensitizes distant tumor lesions to anti-
Pd1. A. Experimental setup. B. Biolominescence imaging of contralateral, not virally treated tumors in indicated treatment 
groups. N=5-6 mice/group. C. Symptom-free survival. PBS co-treated with isotype control (N=19) or anti-Pd1 (N=11); 
oHSVULBP3 co-treated with isotype control (N=20) or anti-Pd1 (N=12). Kaplan-Meier curves were compared utilizing the log 
rank test. D. Flow cytometry normalized histograms depicting the Cd45+ immune cell population in mouse glioblastoma-
bearing hemispheres 7 days after injection with PBS or oHSVULBP3 (left panel), and distant untreated hemispheres from the 
same mice (right panel). E. Cd8+ cell counts in distant hemispheres upon unilateral treatment with PBS or oHSVULBP3 in 
combination with anti-Pd1 or isotype 10 mg/kg i.v. every other day. Immunohistochemistry was done on day 7 after initiation 
of treatment. N=4 mice per group. Unpaired, two-tailed t-test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. F. 
Representative immunohistochemistry staining of Cd8+ cells in untreated tumor-bearing hemispheres. Upper panels, PBS; 
lower panels, oHSVULBP3 co-treated with anti-Pd1; Scale bars, 100 μm.  
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Figure 4. Anti-Pd1 augments oHSVULBP3 driven distant TAM activation. Bilateral XFM-Luc:PDGF,Cre glioblastoma-
bearing mice were treated unilaterally as indicated in Figure 3A. A. Flow cytometry time-course analysis of the tumor-
infiltrating monocyte fraction (Cd45+;Cd11b+;Ly6chigh;Ly6g-). N=5-8 mice/group/timepoint; mean +/- standard error; 
unpaired 2-tailed t-test, ** p<0.01, *** p<0.001, **** p<0.0001. B. Representative H&E or Iba1 immunohistochemistry 
stainings in adjacent slides of untreated hemispheres (distant), contralateral to tumors injected with PBS or oHSVULBP3. Green 
lines, pseudopalisading cells around necrosis; scale bars: 200 μm. C. Flow cytometry time-course analysis of the TAM 
fraction (Cd45+;Cd11bhigh;Ly6clow;Ly6g-). N=5-8 mice/group/timepoint; mean +/- standard error; unpaired 2-tailed t-test, ** 
p<0.01, *** p<0.001, **** p<0.0001. D. Volcano plot of differentially expressed myeloid genes in distant tumors, 
contralateral to oHSVULBP3 treatment, with versus without co-treatment with anti-Pd1 (N=5 per group). E. Gene set 
enrichment analysis of genes up-regulated in distant tumors upon add-on of anti-Pd1 to oHSVULBP3 (magenta in panel D).  
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Table S1 – Materials 
 
 SOURCE IDENTIFIER 
Antibodies 
Immunohistochemistry/immunofluorescence   
Rat anti-mouse/human CD3e (1:300) Biorad/Serotec MCA1477 
Rat anti mouse-Cd8a (1:300) ebioscience 14-0808-80 
Rabbit anti-mouse/human Iba1 (1:500) Wako 019-19741 
Goat anti-Iba1 (1:500) Abcam AB-5076 
Rabbit anti human/mouse-FoxP3 (1:50) R&D MAB8214 
Rabbit anti-mouse Olig2 (1:300) Millipore AB9610 
Chicken anti-GFP (1:5000) Invitrogen A10262 
Rabbit anti-Neurofilament heavy chain (1:500) USB N2160-06L 
Biotinylated goat anti-rabbit (1:300) Vector BA-1000 
Biotinylated goat anti-rat (1:300) Vector BA-9400 
Donkey anti-rabbit Cy3 (1:200) Jackson Immuno 711-165-152 
Donkey anti-goat 647 (1:200) Jackson Immuno 705-605-147 
Donkey anti-chicken 488 (1:200) Jackson Immuno 703-545-155 
   
ULBP3 binding studies   
hIgG1-Fc-APC R&D Systems FAB110A 
Anti-human   
CD3-BV650 BioLegend 317324 
CD19-BV510 BioLegend 363020 
CD14-BV421 BioLegend 325628 
CD16-FITC BioLegend 360716 
CD56-PE/Cy7 BioLegend 318318 
CD163-PE R&D Systems FAB1607P 
Anti-mouse   
NKp46-BV711 BioLegend 137621 
Cd3-BV510 BioLegend 100234 
Cd19-BV421 BioLegend 115538 
Ly-6G-FITC BioLegend 127606 
F4/80-PE/Cy7 BioLegend 123114 
   
Flow cytometry   
Cd45-Alexa Fluor 700 Biolegend 30-F11 
Cd3-BV711 Biolegend 17A2 
Cd4-BV786 Biolegend RM 4-5 
Cd8-PerCP/Cy5.5 Biolegend 53-6.7 
Pd1-BV421 Biolegend 29F.1A12 
Tim3-APC Biolegend RMT3-23 
Cd19-PECy7 BD 1D3 
Cd274-PE Biolegend 10F.69G2 
Cd274-BV421 BD MIH5 
Ly6C-FITC Biolegend HK1.4 
Ly6G-PE-CF594 BD 1A8 
Cd11b-PECy7 eBioscience M1/70 
Cd11c-BV605 Biolegend N418 
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MHC-II-APC eBioscience M5/114.15 
Cd62L-BV605 Biolegend MEL-14 
Cd44-FITC Biolegend IM7 
Cd44-BUV395 BD IM7 
   
Virus Strains 
oHSV Oncorus ONCR2 
oHSVULBP3 Oncorus ONCR7 
nrHSV Oncorus FDN17 
   
Chemicals and Recombinant Proteins 
Rat IgG2aκ (isotype control for anti-PD-1) endotoxin 
low 
 
BioXcell BE0089 
Rat IgG2bκ (isotype control for anti-PD-L1)  
endotoxin low BioXcell BE0090 
Mouse IgG2bκ (isotype control for anti-CTLA4)  
endotoxin low BioXcell BE0086 
Rat anti-mouse-Pd-L1 mAb endotoxin low BioXcell BE0101 
Rat anti-mouse-Pd-1 mAb endotoxin low BioXcell BE0146 
Mouse anti-mouse-Ctla4 mAb endotoxin low BioXcell BE0164 
D-luciferin Caliper Life Sciences #119222 
Live/Dead Yellow Amine Life Technologies L34968 
   
   
Commercial Assays 
Fugene 6 transfection kit Roche E2691 
QIAGEN RNeasy FFPE kit Qiagen 73504 
nCounter Mouse immunology panel Nanostring XT-CSO-MIM1-12 
nCounter Mouse myeloid innate immunity panel Nanostring XT-CSO-MMII2-12 
LDH release assay kit Roche 11 644 793 001 
AllPrep RNA/Protein kit Qiagen 80404 
   
Experimental Models: Cell Lines 
DF-1 Chicken fibroblast cell line ATCC CRL-12203 
Primary mouse derived glioblastoma cells 
This paper  
(N/tva;Cdkn2a-/-
;Ptenfl/fl 
:PDGFB,Cre) 
N/A 
   
Experimental Models: Organisms/Strains 
Tg(NES-TVA);Cdkn2a (Ink4a-Arf)-/-;Ptenfl/fl; LSL 
Luciferase This paper N/A 
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Recombinant DNA 
RCAS-HA-PDGFB Ozawa et. al  2015,  Eric Holland N/A 
RCAS-Cre Ozawa et. al  2015, Eric Holland N/A 
RCAS-shPten_2 Ozawa et. al  2015, Eric Holland N/A 
   
Software 
Prism 7 GraphPad N/A 
FlowJo Tree star N/A 
nSolver Nanostring N/A 
R R-project N/A 
Image J NIH N/A 
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Note S1 – Optimizing oHSV attenuation for the treatment of brain tumors 
 
oHSV strains are among the most thoroughly studied oncolytic viruses, because their 
DNA-genome renders them genetically stable, their large size enables integration of 
several transgenes, and the vector immunogenicity limits systemic infection and provides 
a margin of safety (1). However, neurotropism of wildtype HSV requires attenuation in 
order to prevent destruction of healthy brain tissue. The most commonly utilized strategy 
for HSV-attenuation is deletion of the gene encoding the neurovirulence factor ICP34.5 
(1). A caveat of this approach is that loss of ICP34.5 sensitizes oHSV-infected cells to 
interferon-mediated repression of viral replication and spreading (2). In patients, this 
limitation can be compensated by repeat intratumoral oHSV injections. For brain tumors, 
this approach is challenging and the use of a potently replicating oHSV is desirable. As 
an alternative to ICP34.5 deletion, we included multiple response elements for the brain 
abundant tumor suppressor miR-124 into the 3’ untranslated region of the gene encoding 
infected cell protein (ICP)4, a transcription factor essential for HSV replication 
(3)(Figure S2A). 
Mouse glioblastoma cell lines derived from XFM-Luc:PDGF,Cre glioblastomas were 
lysed when exposed to increasing oHSV doses for 72 hours (p<0.001, Figure S2B). To 
determine the specificity of miR-124 attenuation, we first performed co-
immunofluorescence staining upon intratumoral injection in XFM-Luc:PDGF,Cre mouse 
glioblastomas. The enhanced green fluorescent protein (eGFP), which is expressed with 
the UL44 gene to mark viral replication, was not detected in neurofilament stained 
neurons (Figure S2C). Instead, eGFP was predominantly detected in the Olig2+ 
population, which comprises mostly glioblastoma cells, and in a subset of Iba1+ TAMs 
	 6	
(Figure S2D). eGFP labeling of TAMs could either be due to infection or to phagocytosis 
of Olig2-expressing tumor cells by the TAMs. To further explore this issue and determine 
if oHSV-infected tumor cells showed enhanced phagocytosis by TAMs, we isolated 
Cd45high;Cd11b+;Ly6clow TAMs from untreated XFM-Luc:PDGF,Cre glioblastomas for 
co-incubation with dye-labeled tumor cell lines derived from the same model (1:1 ratio, 3 
hours). Subsequent flow cytometry determined that overnight oHSV infection enhanced 
phagocytosis of dye-labeled tumor cells by approximately 3-fold (Figure S2E). 
In XFM-Luc:PDGF,Cre mice not infected with RCAS vectors, intracranial injection of 
miR-124-attenuated oHSV at doses of 3x106 plaque forming units (PFU, N=23 mice), but 
not of 1x106 PFU (N=14) induced transient shivering and lethargy for up to three days. 
These symptoms resolved in all cases and never resulted in death, persistent neurologic 
symptoms or histologic signs of encephalitis. In all subsequent experiments, oHSV 
treatment was performed with 1x106 PFU injected directly into tumors utilizing the 
identical coordinates as for RCAS injection to initiate tumor formation. We conclude that 
intracranial injection of miR-124-attenuated, ICP34.5+/- oHSV was a safe and tumor cell 
specific approach to enhance phagocytosis by TAM.  
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Figure	S1.	XFM-Luc:PDGF,Cre	mouse	glioblastomas	recapitulate	molecular	features	of	human	glioblastoma.	A.	
Genome	plot	visualizing	frequencies	of	copy	number	gains	(red)	and	losses	(blue)	along	the	genome	in	IDH	wildtype,	
Cdkn2a-/-	human	glioblastoma.	B.	RCAS	vectors	utilized	for	infection	of	NES+	brain	cells	in	indicated	transgenic	mice.	
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Figure	S2,	continued	on	next	page	
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Figure	S2,	legend	on	next	page	
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Figure	S2.	miR-124-attenuated	oHSV	lyses	tumor	cells	and	promotes	phagocytosis,	and	arming	oHSV	
with	ULBP3	promotes	antigen	processing	and	presentation	in	an	NKG2D	and	NK-cell	independent	
manner.	A.	Vector	map	of	oHSVULBP3.	T124,	miR-124	response	elements.	B.	Left	panel:	dose-response	of	
the	lytic	potential	of	the	oHSV	backbone	in	primary	mouse	glioblastoma	cells	derived	from	XFM-
Luc:PDGF,Cre	tumors.	LDH	release	is	expressed	as	percentage	of	triton-lysed	cells	(N=4	technical	
replicates).	nrHSV,	non-replicating	HSV-strain	(FDN17).	Cells	were	infected	48	h	prior	to	analysis.	MOI,	
moiety	of	infection.	Right	panel:	representative	fluorescence	microscopic	image	of	XFM-Luc:PDGF,Cre	
cells	infected	with	100	MOI	oHSV;	eGFP	detection	marks	viral	replication.	C,	D.	XFM-Luc:PDGF,Cre	
glioblastomas	were	injected	with	miR-124-attenuated	oHSV	(1x106	PFU)	on	day	14	after	tumor	initiation	
and	were	sacrificed	on	day	21.	eGFP	marks	viral	replication.	Olig2	marks	predominantly	tumor	cells.	Co-
immunofluorescence	stainings	were	done	for	(C)	eGFP	and	neurofilament	(NF),	and	(D)	eGFP,	Iba1	and	
Olig2.	Scale	bar,	50	μm. E.	Flow	cytometry	of	XFM-Luc-derived	TAM	co-incubated	for	4	h	with	dye-
labelled		XFM-Luc	glioblastoma	cells	(1:1	ratio,	3	hours).	Cancer	cells	were	infected	with	10	MOI	oHSV	or	
treated	with	PBS	overnight.	Percentages	indicate	the	fraction	of	macrophages	that	were	double-positive	
for	the	TAM	marker	F480,	and	for	the	cell	tracer	pacific	blue,	indicating	phagocytosis	of	cancer	cells.	F.	
Bioluminescence	imaging	of	tumor	growth.	XFM-Luc:PDGF,Cre	mouse	glioblastomas	were	treated	as	
indicated	on	day	14	after	tumor	initiation.	Luciferin	emission	was	measured	every	2-3	days.	Upper	panel:	
representative	measurement;	lower	panel:	median	tumor	growth.	G.	Ratios	of	the	maximal	number	of	
Cd8+	over	FoxP3+	cells	per	high	power	field	(HPF,	40x)	in	tissue	slides	of	mice	sacrified	on	day	7	after	
indicated	treatment	determined	by	immunohistochemistry	(N=4	mice/group).	H.	Counts	of	Cd8+	cells	
(N=4	mice/group)	of	mice	sacrified	on	day	7	after	initiation	of	indicated	treatments	and	stained	by	
immunohistochemistry.	aPD1,	anti-PD-1	10	mg/kg	i.v.	every	other	day;	iso,	IgG	isotype	control.	I.	Flow	
cytometry	of	the	Cd8+	effector	T-cell	fractions	on	day	7	(N=6-8	mice/group).	J-L.	Flow	cytometry	of	whole	
tumors	treated	with	PBS	or	oHSVULBP3	(N=8	mice/group)	of	mice	sacrified	on	day	7	after	initiation	of	
indicated	treatments.	*	p<0.05,	****	p<0.001.	M.	nCounter	myeloid	gene	expression	analysis	of	tumor-
bearing	mouse	brain	hemispheres	treated	with	oHSVULBP3		or	PBS	followed	by	geneset	enrichment	
analysis	of	gene	ontology	(GO)	terms	annotated	to	biological	processes.	N.	Three-dimensional	structure	
of	ULBP3	and	NKG2D.	The	protein	modeling	portal	was	accessed	to	explore	interactions	of	ULBP3	with	
mouse	and	human	NKG2D.	Human	NKG2D	forms	a	homodimer	(cyan,	green)	with	ULBP3	(magenta).	
Amino	acids	that	differ	with	mouse	NKG2D	are	shown	in	red,	amino	acids	involved	in	the	interaction	
surface	are	shown	in	blue/orange	and	polar	contacts	between	chains	are	depicted	with	yellow	dashes.	O.	
Flow	cytometry	to	determine	interactions	of	Fc-tagged	ULBP3	with	immune	cells	in	the	presence	or	
absence	of	anti-NKG2D	blocking	antibodies	in	human	peripheral	blood	mononuclear	cells	(PBMC)	from	
N=3	healty	donors	(left	panel)	and	splenocytes	from	N=3	wildtype	C57/bl6	mice	(middle	panel).	The	
presence	of	NKG2D	was	determined	on	mouse	splenocytes	(right	panel).	T,	T-cells;	NK,	NK-cells;	NT,	NKT-
cells;	B,	B-cells;	Mc,	macrophages;	Mo,	monocytes.	P.	Gene/geneset	overlap	matrix	of	ULBP3	interaction	
partners	(Huttlin	et	al.	2017)	with	GO	biological	process	genesets	was	generated	utilizing	the	open	access	
gene	set	enrichment	software	deposited	with	the	MSigDB	database	v6.2	from	Broad	Institute.	FDR,	false-
discovery	rate. 
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Figure	S3,	legend	on	next	page	
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Figure	S3.	Localized	oHSVULBP3	infection	elicits	a	distant	immune	response	and	sensitizes	distant	tumor	
lesions	to	anti-PD-1.	A.	Schematic	of	the	bilateral	XFM-Luc:PDGF,Cre/shPten	tumor	model	utilized	for	
bioluminescence	imaging	of	distant	(abscopal)	tumor	growth	(right	panel)	and	representative	images	
from	day	10	after	initiation	of	indicated	treatments.	aPD1,	anti-PD-1;	iso,	IgG	isotype	control.	Treatment	
schedule	as	in	Figure	4A.	B.	Survival	of	XFM-Luc	mice	bearing	unilateral	PDGF-driven	tumors	co-
transduced	with	RCAS-Cre	(N=11)	or	RCAS-shPten	(N=9).	C.	Survival	of	XFM-Luc	mice	bearing	bilateral	
tumors	driven	by	PDGF	and	Cre/shPten	after	unilateral	treatment	with	oHSVULBP3	(Figure	S4A).	Left	panel:	
Indicated	treatment	groups	from	Figure	4B	(isotype,	N=19;	anti-PD-1,	N=12).	Right	panel:	Only	mice	
surviving	>	7	days	are	depicted	(isotype,	N=5;	anti-PD-1,	N=6).	Kaplan-Meier	curves	were	compared	
utilizing	the	log	rank	test.	D.	Normalized	gene	expression	levels	of	viral	antigens	in	PBS-treated	tumors	
(negative	control),	oHSV-infected	tumors	and	in	contralateral	untreated	tumors.	A	customized	nCounter	
panel	was	utilized	on	day	7	after	oHSV	infection.	Unpaired,	two-tailed	t-test.	
E.	Flow	cytometry	to	determine	the	fractions	of	T	central	memory	(TCM)	cells	in	the	tumor	infiltrating	
Cd4+	(left	panel)	and	Cd8+	(right	panel)	lymphocyte	populations	in	bilateral	XFM-Luc:PDGF,Cre	tumors.	
Treated	and	distant	(contralateral	untreated)	tumor-bearing	hemispheres	were	analyzed	separately.	N=5	
mice	per	group	were	analyzed	three	days	after	unilateral	intratumoral	injection	of	PBS	or	oHSVULBP3.	
Unpaired,	two-tailed	t-test.	F.	Flow	cytometry	to	determine	the	fractions	of	activated	Cd69+	(left	panel)	
and	Nkg2D+	(right	panel)	tumor-infiltrating	Cd8+	lymphocytes	in	bilateral	XFM-Luc:PDGF,Cre	tumors.	N=5	
mice	per	group	were	analyzed	three	days	after	unilateral	intratumoral	injection	of	PBS	or	oHSVULBP3.	
Unpaired,	two-tailed	t-test.	G.	Flow	cytometry	time-course	analysis	of	the	Cd44-;Cd62L+	fraction	of	naïve	
tumor-infiltrating	Cd45+;Cd3+;Cd8+	lymphocytes	in	bilateral	oHSV-Luc:PDGF,Cre	tumors	treated	
unilaterally	with	PBS	(N=6)	or	oHSVULBP3	(N=8).	Left	panel:	treated	hemispheres;	right	panel:	distant	
hemispheres	(contralateral,	untreated).	Curves	were	compared	by	linear	regression.	H.	Flow	cytometry	of	
mouse	glioblastoma-bearing	hemispheres	7	days	after	injection	with	PBS	or	oHSVULBP3	(closed	symbols,	
treated),	or	corresponding	contralateral	hemispheres	(open	symbols,	distant).	Fractions	in	
Cd45+;Cd3+;Cd8+	T-cells	positive	for	both	surface	exhaustion	markers	PD-1	and	Tim3	are	depicted.	
Unpaired	2-tailed	t-test,	*	p<0.05,	****	p<0.0001.	
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Figure	S4.	Anti-PD-1	augments	oHSVULBP3	driven	abscopal	TAM	activation.	A.	Immunohistochemistry	for	
Iba1	in	the	contralateral	hemispheres	upon	unilateral	treatment	with	PBS	or	oHSVULBP3	in	combination	
with	anti-PD-1	or	isotype	10	mg/kg	i.v.	every	other	day.	The	overall	surface	covered	with	Iba1+	cells	was	
determined	at	low	magnification	(4x)	utilizing	Image	J.	N=4	mice	per	group.	Unpaired,	two-tailed	t-test.	
B.	Flow	cytometry	normalized	histograms	depicting	the	Cd44+	cell	population	in	mouse	glioblastoma-
bearing	hemispheres	14	days	after	injection	with	PBS	or	oHSVULBP3	(left	panel),	and	abscopally	in	distant	
untreated	tumor-bearing	hemispheres	from	the	same	mice	(right	panel).	C.	Flow	cytometry	to	determine	
the	median	fluorescence	intensity	(MFI)	of	MHC-II	on	the	cell	surface	of	Cd11c+	dendritic	cells	(DC)	in	
bilateral	XFM-Luc:PDGF,Cre	tumors.	N=6	mice	per	group	were	analyzed	7	days	after	unilateral	
intratumoral	injection	of	PBS	or	oHSVULBP3.	Unpaired,	two-tailed	t-test.	D.	Ratio	of	normalized	
Cd68/Cd163	mRNA	counts	determined	by	nCounter	myeloid	gene	expression	panel	analysis	in	
contralateral,	untreated	tumors	of	the	bilateral	XFM-Luc:PDGF,Cre	model.	N=5	mice	per	group.	Unpaired,	
two-tailed	t-test.	E.	Geneset	enrichment	analysis	of	up-regulated	KEGG	pathways	abscopally	in	
untreated,	distant	tumors	of	unilaterally	oHSVULBP3	treated,	bilateral	XFM-Luc:PDGF,Cre	glioblastoma-
bearing	mice.	PBS-treated	tumors	were	utilized	as	the	reference.	N=5	mice	per	group.	F,	G.	nCounter	
myeloid	gene	expression	analysis	of	tumor-bearing	mouse	brain	hemispheres	treated	with	anti-PD-1	or	
isotype	10	mg/kg	i.v.	every	other	day,	followed	by	geneset	enrichment	analysis	of	gene	ontology	(GO)	
terms	annotated	to	biological	processes	(F)	or	KEGG	pathways	(G).	
*	p<0.05,	**	p<0.01 
